NAS10029,813+0.55%S&P7,744+0.28%GOLD$4,077+0.07%BTC$81,598+0.98%VIX16.87−3.71%latest tape · as of 20:04 UTC
The Screen · Consumer Defensive · Confectioners
Mondelez International
MDLZ · a US exchange · USD · Market cap $80.9B · 91,000 employees
Mondelez International, Inc., through its subsidiaries, manufactures, markets, and sells snack food and beverage products in Latin America, North America, Asia, the Middle East, Africa, and Europe.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.52, read 2026-10-27
Ethical passes the values gate
Price62.35 USD
Fair value68.65
Ethical score83.9/100
RatingAVOID
Our investment reviews on this name
2026-10-18Read Markup63.03-1.1% to today Distribution gives way to Markup
2026-10-11Read Distribution60.25+3.5% to today Markdown gives way to Distribution after a 6% slide in 6 weeks
2026-08-29Read Markdown64.14-2.8% to today ✓Accumulation gives way to Markdown
2026-07-02Read Accumulation62.04+0.5% to today ✓First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Mondelez International holds its Markup at $62.35. The statistical read favours the sellers, held for 3 days.
As held on the ledger · 2026-10-27
Phase
Markup
Quantitative state
The statistical read favours the sellers, held for 3 days
Price at the screen
$62.35
Valuation
22.75 trailing · 18.73 forward price to earnings
Values screen
PASS· score 83.9
Beta
0.39
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
30.50%
Below 33%
Interest-bearing debt is just 30.5% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.93%
Below 33%
Cash held in interest-bearing accounts and securities is 0.9% of assets, under the one-third limit.
Pass
Receivables
8.43%
Below 49%
Money owed to the company is 8.4% of assets, under the 49% limit.
Pass
Revenue purity
0.82%
Below 5%
Only 0.8% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Mondelez International clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 31%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-10-27. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when MDLZ's ethical verdict changes
Today MDLZ passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Conscience Overlay
Conscience flag · BDS Movement
The quantitative screen above is arithmetic and this name passes it. Separately, community boycott lists cite this company: Cited by BDS movement for Cadbury and other brand operations in Israel. The desk records that flag here without folding it into the verdict: the screen measures the balance sheet, the overlay informs the conscience, and they are different judgements that belong to different owners. The second one is yours.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads AVOID: it trades at roughly a 9% discount to our $68.65 fair value, narrow competitive moat, 4.10% revenue growth.
Fair value range in USD, drawn from the 2026-10-27 screen. The gold marker is the market price at the same screen. A 8.9% margin of safety to the base estimate.
Third-party analyst targets: 22 covering, consensus Buy. The average target sits +12% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-27 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Familiar Snacks Fail to Clear Valuation Bar
Walk down any supermarket aisle and Mondelez products sit on the shelves in dozens of countries. The business sells biscuits, chocolate and baked snacks at scale, yet growth sits at just 8% while margins remain stuck at 7% and returns on equity reach only 10%.
We pass because the numbers do not justify ownership. Shares trade at 18.1 times forward earnings with a narrow moat and only an 11% margin of safety to our fair value. Analyst targets cluster near 68 yet the modest profitability and limited pricing power leave little room for error if costs rise or volumes soften.
Consumer staples can still face input inflation and shifting tastes toward healthier options. A defensive label does not remove those pressures when returns stay this ordinary. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
MDLZ trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-28Markup$63.03+0.0%Entry 22
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 6% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 1%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (25 analysts) rates it buy, with a mean price target of $67. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Markup$63.03+0.0%Entry 21
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 6% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 1%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (25 analysts) rates it buy, with a mean price target of $67. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Markup$63.03+0.0%Entry 20
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 6% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 1%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (25 analysts) rates it buy, with a mean price target of $67. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markup$63.03+0.0%Entry 19
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 1%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (25 analysts) rates it buy, with a mean price target of $67. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Markup$63.03+0.0%Entry 18
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 1%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (25 analysts) rates it buy, with a mean price target of $67. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Markup$63.03+0.0%Entry 17
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 1%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (25 analysts) rates it buy, with a mean price target of $67. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Markup$63.03+0.0%Entry 16
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 7% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 1%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (25 analysts) rates it buy, with a mean price target of $67. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Markup · changed$63.03+4.6%Entry 15
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.6% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 1%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (25 analysts) rates it buy, with a mean price target of $67.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 1%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (25 analysts) rates it buy, with a mean price target of $67.
2026-10-02Markdown$60.25-6.1%Entry 13
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 6.1% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are down 1%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (25 analysts) rates it buy, with a mean price target of $67.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
